Publications by authors named "Enrico Matteini"
Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series.
Clin Cosmet Investig Dermatol
October 2024
Article Synopsis
- - Alopecia areata is an autoimmune disorder that damages hair follicles on the scalp and body, leading to hair loss.
- - Janus kinase inhibitors are effective in treating adults with this condition, while topical treatments like Brevilin-A have shown promise for children and adolescents with mild to moderate cases.
- - Brevilin-A, derived from Centipeda minima, works by blocking specific signaling pathways and has been successfully used in pediatric patients, indicating it could be a safe and effective option for challenging cases of alopecia areata in younger populations.
Background: Alopecia areata (AA) is an organ-specific autoimmune disease that affects the hair follicles of the scalp and the rest of the body causing hair loss. Due to the unpredictable course of AA and the different degrees of severity of hair loss, only a few well-designed clinical studies with a low number of patients are available. Also, there is no specific cure, but topical and systemic anti-inflammatory and immune system suppressant drugs are used for treatment.
View Article and Find Full Text PDFBackground: Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK).
Research Design And Methods: We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events.
Objective: The main outcome of this study was the evaluation of clinical characteristics, comorbidities, and therapeutic approaches in patients with vulvar lichen sclerosus (VLS) aged from childhood to perimenopause. Secondly, it was intended to compare these characteristics according to the menarchal status.
Methods: Patients less than 45 years of age with a diagnosis of VLS from January 2002 to June 2022 in 10 referral centers were included in this retrospective longitudinal study.